[go: up one dir, main page]

AR127519A2 - Anticuerpos anti-cd98 y usos de estos - Google Patents

Anticuerpos anti-cd98 y usos de estos

Info

Publication number
AR127519A2
AR127519A2 ARP220102972A ARP220102972A AR127519A2 AR 127519 A2 AR127519 A2 AR 127519A2 AR P220102972 A ARP220102972 A AR P220102972A AR P220102972 A ARP220102972 A AR P220102972A AR 127519 A2 AR127519 A2 AR 127519A2
Authority
AR
Argentina
Prior art keywords
antigen
antibodies
conjugates
antibody
therapeutic
Prior art date
Application number
ARP220102972A
Other languages
English (en)
Inventor
Suzanne Edavettal
Sanjaya Singh
Derrick Domingo
Deepti Wilkinson
Pilar Cejudo-Martin
Pharavee Jaisprasart
Brian Geist
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR127519A2 publication Critical patent/AR127519A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen anticuerpos anti-CD98 monoclonales y fragmentos de unión al antígeno de estos para suministrar un agente al cerebro de un sujeto que lo necesita. También se describen conjugados y construcciones de fusión que contienen el anticuerpo anti-CD98 o fragmento de unión al antígeno de este acoplado a un agente terapéutico o de diagnóstico, tal como un segundo anticuerpo y fragmento de unión al antígeno de este, para tratar o detectar un trastorno neurológico y/o suministrar un agente terapéutico o de diagnóstico a través de la barrera hematoencefálica. También se describen ácidos nucleicos que codifican los anticuerpos, conjugados y constructos de fusión y células huésped recombinantes relacionadas.
ARP220102972A 2020-04-08 2022-10-31 Anticuerpos anti-cd98 y usos de estos AR127519A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063006988P 2020-04-08 2020-04-08
US202063035961P 2020-06-08 2020-06-08

Publications (1)

Publication Number Publication Date
AR127519A2 true AR127519A2 (es) 2024-01-31

Family

ID=78022989

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP220102971A AR127518A2 (es) 2020-04-08 2022-10-31 Anticuerpos anti-cd98 y usos de estos
ARP220102972A AR127519A2 (es) 2020-04-08 2022-10-31 Anticuerpos anti-cd98 y usos de estos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP220102971A AR127518A2 (es) 2020-04-08 2022-10-31 Anticuerpos anti-cd98 y usos de estos

Country Status (14)

Country Link
US (1) US20230174669A1 (es)
EP (1) EP4132974A4 (es)
JP (1) JP2023520811A (es)
KR (1) KR20220166304A (es)
CN (1) CN115698074A (es)
AR (2) AR127518A2 (es)
AU (1) AU2021253821A1 (es)
BR (1) BR112022020453A2 (es)
CA (1) CA3179922A1 (es)
IL (1) IL297143A (es)
MX (1) MX2022012633A (es)
PH (1) PH12022552667A1 (es)
TW (1) TW202142569A (es)
WO (1) WO2021205361A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697393A (zh) * 2020-04-08 2023-02-03 詹森生物科技公司 抗PHF-tau抗体及其用途
EP4561614A1 (en) * 2022-07-29 2025-06-04 Alector LLC Cd98hc antigen-binding domains and uses therefor
EP4565331A1 (en) 2022-08-05 2025-06-11 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors
TW202515915A (zh) * 2023-06-21 2025-04-16 美商戴納立製藥公司 抗ｐｉｌｒａ抗體、其用途以及相關方法及試劑
WO2025152912A1 (en) * 2024-01-15 2025-07-24 4B Technologies (Suzhou) Limited Cd98hc antigen-binding protein and use thereof
WO2025166042A1 (en) * 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025247301A1 (en) * 2024-05-30 2025-12-04 Sironax Switzerland Gmbh Novel antibodies specific for cd98 heavy chain and methods of uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120053525A (ko) * 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
US20130052197A1 (en) * 2010-03-26 2013-02-28 The University Of Tokushima Novel anti-cd98 antibody and use thereof
AU2012340623A1 (en) * 2011-11-23 2014-07-17 Igenica Biotherapeutics, Inc. Anti-CD98 antibodies and methods of use thereof
AU2015360579A1 (en) * 2014-12-10 2017-05-18 Genentech, Inc. Blood brain barrier receptor antibodies and methods of use
CN105385694B (zh) * 2015-11-20 2019-01-18 中国人民解放军第四军医大学 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用
MX2018015268A (es) * 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
US12258414B2 (en) * 2018-06-22 2025-03-25 Ossianix, Inc. Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries

Also Published As

Publication number Publication date
EP4132974A4 (en) 2024-05-08
EP4132974A1 (en) 2023-02-15
MX2022012633A (es) 2023-01-11
JP2023520811A (ja) 2023-05-19
PH12022552667A1 (en) 2023-01-09
CA3179922A1 (en) 2021-10-14
AU2021253821A1 (en) 2022-11-24
WO2021205361A1 (en) 2021-10-14
AR127518A2 (es) 2024-01-31
KR20220166304A (ko) 2022-12-16
IL297143A (en) 2022-12-01
CN115698074A (zh) 2023-02-03
US20230174669A1 (en) 2023-06-08
BR112022020453A2 (pt) 2022-11-29
TW202142569A (zh) 2021-11-16

Similar Documents

Publication Publication Date Title
AR127521A2 (es) Composiciones y métodos para suministro a la barrera hematoencefálica
AR127518A2 (es) Anticuerpos anti-cd98 y usos de estos
CO2021006092A2 (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
BR112015010046A2 (pt) Proteínas de ligação a antígeno ou um fragmento de ligação a antígeno da mesma e seu método de produção, vetor, célula hospedeira de microrganismo transgênico, imunoconjugado e seu uso, composição farmacêutica e hibridoma murino
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
CR9236A (es) Moleculas de union al antigeno que fijan eger, vectores que las codifican y usos de las mismas
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1
CO6180451A2 (es) Polipeptidos heterodimericos il -17 a/f y usos terapeuticos de los mismos
JP2015532102A5 (es)
MX2024010983A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
MX2023003039A (es) Agentes y metodos para el suministro dirigido a celulas.
BR112023019205A2 (pt) Anticorpos humanizados contra tau de filamento helicoidal pareado e usos dos mesmos
AR124455A2 (es) Proteínas de unión específicas y sus usos
BR112021017046A2 (pt) Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos
CL2025002218A1 (es) Células que expresan un car anti-mesotelina
Zhou et al. DEC205-DC targeted DNA vaccines to CX3CR1 and CCL2 are potent and limit macrophage migration
AR121802A1 (es) Anticuerpos anti-cd98 y usos de estos
AR121803A1 (es) Composiciones y métodos para suministro a la barrera hematoencefálica
MX2024011081A (es) Anticuerpos multiespecíficos y usos de estos.
WO2023060213A3 (en) Incenp targeting polypeptides for detection and treatment of cancer
CO2025009946A2 (es) Proteínas de unión al antígeno anti-tnfr2 y sus usos
BR112023025810A2 (pt) Agentes e métodos para ativação e direcionamento de células imunes efetoras
MX2024011083A (es) Anticuerpos multiespecíficos y usos de estos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal